Matt Schmidt
Director of Third-Party Quality Management Merck & Co
Seminars
Wednesday 22nd July 2026
Round Table Discussion: Streamlining CDMO & Vendor Selection at GMP-Grade to Ensure Quality, Cost Effectiveness & Validation for Novel mRNA & CGT Therapies
1:30 pm
- How to evaluate and select mRNA-specialized CDMOs that align with project needs, timelines, and modality complexity?
- Establishing collaborative data-sharing and tech transfer models to ensure transparency and reduce rework
- Managing regulatory, quality and IP risks while leveraging partner strengths for faster IND or clinical production
